Core Insights - The company is expected to achieve profitability by 2025, with significant breakthroughs in international expansion and promising clinical data for its product, Westoroni, in the pancreatic cancer field [1][2]. Financial Performance - The company's revenue forecast for 2025 is projected at 910 million yuan, representing a year-on-year growth of 38.32% [2]. - The net profit attributable to shareholders is expected to be 53.46 million yuan, marking a turnaround from previous losses [2]. - Key products, including Sigleth sodium, have seen a sales revenue increase of approximately 123% year-on-year, while Sidabamine, despite facing price reductions from insurance, still achieved a 16% growth [2]. Recent Developments - On February 10, 2026, the company announced progress in its international expansion, granting exclusive rights for Sidabamine to Russian pharmaceutical company Nizhpharm in the CIS and Central Asia, which includes an upfront payment of 10 million yuan [3]. - The updated Phase II clinical data for Westoroni in combination chemotherapy shows a 50% objective response rate (ORR) and a median progression-free survival (mPFS) of 9.1 months, supporting further development [3]. Stock Performance - Over the past week (February 5 to 11, 2026), the company's stock price fluctuated between a high of 32.47 yuan and a low of 30.75 yuan, with a total decline of 0.76% [4]. - On February 10, the stock price increased by 1.28%, with a net inflow of 28.19 million yuan from major funds; however, it closed at 31.21 yuan on February 11, down 1.73% for the day [4]. - The financing balance has been increasing, with a recent growth of 5.57% over the past five days [4].

以上内容基于公开资料整理，不构成投资建议。 近7个交易日(2026年2月5日至11日)，博瑞医药股价波动明显。截至2月11日收盘，股价报46.15元，当日 下跌1.77%，周内累计跌幅约1.83%；区间最高价为2月10日的47.77元，最低价为2月4日的45.60元。资 金流向方面，2月10日主力资金净流入2162.91万元，但2月11日转为净流出2762.89万元，显示短期资金 分歧。整体来看，股票换手率维持在1%左右，估值水平较高(市盈率TTM约314倍)，近期表现弱于医药 生物板块(板块同期涨跌幅-0.32%)。 经济观察网近期，博瑞医药(688166)受到机构关注。2026年2月9日披露的调研信息显示，知名私募重阳 投资和公募中银基金均参与了公司路演活动，重点关注创新药管线进展。其中，BGM0504注射液国内2 型糖尿病和减重适应症III期临床已完成入组，美国减重适应症处于III期方案完善阶段，印尼已启动三期 临床；口服BGM0504片剂中美一期临床进行中。此外，公司布局了GLP-1/GIP双靶点、BGM1812注射 液等多条创新管线，但各项目均处于早期研发阶段，需注意风险。 股票近期走势 ...

药物类型：治疗用生物制品 格隆汇2月11日丨恒瑞医药(01276.HK)公布，近日，公司子公司苏州盛迪亚生物医药有限公司的注射用 瑞康曲妥珠单抗(SHR-A1811)被国家药品监督管理局药品审评中心(以下简称"药审中心")纳入突破性治 疗品种名单，这是瑞康曲妥珠单抗第10项获得突破性治疗认证的适应症。 药物名称：注射用瑞康曲妥珠单抗 受理号：CXSL2000087 申请日期：2025年12月2日 注册分类：1类 拟定适应症(或功能主治)：HER2(ERBB2)激活突变的局部晚期或转移性非小细胞肺癌患者的一线治疗。 理由及依据：经审核，本申请符合《药品注册管理办法》和《国家药监局关于发布＜突破性治疗药物审 评工作程序(试行)＞等三个文件的公告》(2020年第82号)有关要求，同意纳入突破性治疗药物程序。 公司注射用瑞康曲妥珠单抗已于2025年5月在国内获批上市，适用于治疗存在HER2(ERBB2)激活突变且 既往接受过至少一种系统治疗的不可切除的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者。 ...

Core Viewpoint - The company, Yuandong Biotech (688513.SH), has participated in the procurement process for the continuation of drugs whose agreements from the national centralized procurement have expired, with 13 products proposed for selection in this round [1][2]. Group 1: Procurement Details - The company has submitted applications for the continuation procurement organized by Jiangsu, Henan, and Guangdong provinces [1]. - The proposed selected products include 12 that were previously selected in the first to eighth batches of national centralized procurement and one new product, Paricalcitol Injection [1]. - The sales revenue from these products is projected to be approximately 651.20 million yuan in 2024, accounting for 48.25% of the company's total revenue for that year [1]. Group 2: Impact on Revenue - For the period from January to September 2025, the expected sales revenue from these products is about 504.08 million yuan, representing 49.46% of the company's total revenue for that period [1]. - The procurement cycle will last until December 31, 2028, during which medical institutions will prioritize the selected drugs, ensuring the completion of agreed procurement volumes [2]. Group 3: Market Stability - The overall pricing of the procurement is expected to remain stable or decrease further, providing medical institutions with greater choice and ensuring continuity in clinical medication [2]. - Although some selected products may see a price decrease compared to original sales prices, the selection of 13 products allows the company to maintain its market share and enhance the accessibility of these drugs [2].

Core Viewpoint - Luo Xin Pharmaceutical (002793) reported that as of February 10, 2026, the total number of shareholders is 38,789 [1] Group 1 - The company is actively engaging with investors through an interactive platform [1] - The total number of shareholders indicates a growing interest in the company's stock [1]

Core Viewpoint - The announcement highlights that the company's subsidiary, Suzhou Merrion Biopharmaceutical Co., Ltd., has received a breakthrough therapy designation from the National Medical Products Administration for its injectable SHR-A1811, marking the tenth indication for this drug to achieve such recognition [1] Group 1 - The injectable SHR-A1811 has been included in the list of breakthrough therapies by the National Medical Products Administration [1] - This designation signifies a significant milestone for the company, as it reflects the potential of SHR-A1811 in treating specific medical conditions [1] - The achievement of ten breakthrough therapy certifications for SHR-A1811 indicates the drug's promising therapeutic profile and the company's commitment to advancing its development [1]

Group 1 - The core transaction involved 200,000 shares of Rundu Co., with a total transaction value of 2.992 million yuan, representing 1.99% of the total trading volume on that day [1][2] - The transaction price was 14.96 yuan per share, which is an 8.67% discount compared to the market closing price of 16.38 yuan [1][2]

Group 1 - The controlling shareholder and actual controller Zhang Qinghua completed the pledge of 8.75 million shares, accounting for 1.99% of the total share capital, to replace maturing financing on February 11 [1] - As of the announcement date, Zhang Qinghua directly holds 156 million shares, representing 35.53% of the total share capital, with a cumulative pledge of 64.0752 million shares, which is 41.07% of his direct holdings and 14.59% of the total share capital [1] - Zhang Qinghua and his concerted parties collectively hold 166 million shares, with a cumulative pledge of 64.0752 million shares, accounting for 38.70% of the total holdings, indicating that the overall pledge risk is controllable and there is no risk of forced liquidation [1]

公司本次拟中选的4个产品2025年前三季度合计销售额为8,884.75万元，占公司2025年前三季度营业收入 比例为10.16%。在采购周期内，医疗机构将优先使用本次药品接续采购中选药品，并确保完成约定采 购量。若后续签订采购合同并实施，将进一步扩大产品的销量，提高市场占有率，提升公司品牌形象。 博瑞医药(688166.SH)发布公告，近日，公司全资子公司博瑞制药(苏州)有限公司(简称"博瑞制药")参加 了国家组织集采药品协议期满品种接续采购办公室组织的集采药品协议期满品种接续采购。根据接续采 购办公室于2026年2月10日发布的《国家组织集采药品协议期满品种接续采购拟中选结果公示》，公司 阿加曲班注射液等4个药品拟中选本次接续采购。 ...

格隆汇2月11日丨上海医药(601607.SH)公布，根据《中华人民共和国公司法》《公司章程》等有关规 定，经2026 年2月11 日召开的第三届职工代表大会第二次联席会议审议通过，选举赵勇先生为公司第八 届董事会职工代表董事。赵勇先生与经公司股东会选举产生的第八届董事会非职工代表董事共同组成公 司第八届董事会，任职期限为自公司职工代表大会选举之日起至第八届董事会任期届满之日止。 ...